Cargando…
Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer
INTRODUCTION: Total neoadjuvant therapy (TNT) is a new therapeutic strategy in patients with rectal cancer. We examined the role of TNT, in addition to other pre-operative factors, as a predictor for pathologic complete response (pCR). METHODS: A retrospective analysis of all rectal cancer patients...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555694/ https://www.ncbi.nlm.nih.gov/pubmed/36224480 http://dx.doi.org/10.1007/s11605-022-05463-1 |
_version_ | 1784806917556666368 |
---|---|
author | Horesh, Nir Freund, Michael R. Garoufalia, Zoe Gefen, Rachel Nagarajan, Arun Suarez, Eva Emile, Sameh Hany Wexner, Steven D. |
author_facet | Horesh, Nir Freund, Michael R. Garoufalia, Zoe Gefen, Rachel Nagarajan, Arun Suarez, Eva Emile, Sameh Hany Wexner, Steven D. |
author_sort | Horesh, Nir |
collection | PubMed |
description | INTRODUCTION: Total neoadjuvant therapy (TNT) is a new therapeutic strategy in patients with rectal cancer. We examined the role of TNT, in addition to other pre-operative factors, as a predictor for pathologic complete response (pCR). METHODS: A retrospective analysis of all rectal cancer patients who underwent surgery between 2016 and 2021 was conducted. Patients were classified into two groups—pCR group and residual tumor group. Patient data were reviewed and entered into univariate and multivariate analyses to determine predictors of pCR. RESULTS: A total of 172 patients were treated with neoadjuvant therapy and underwent surgery during the study period. Sixty patients (34.9%) were treated with TNT while 112 (65.1%) were treated with traditional neoadjuvant chemoradiation. The overall pCR rate was 25.6% (44 patients), with 31.6% (19 patients) in patients who received TNT compared to 22.3% (25 patients) in patients who received neoadjuvant chemoradiation (NCRT). Univariate analysis of clinical and radiological factors correlated with pCR demonstrated no significant differences between the two groups in cT stage (p = 0.46), cN stage (p = 0.52), positive circumferential resection margin (CRM) (p = 0.72), tumor location (p = 0.35), symptomatic presentation (p = 0.09), and anal sphincter involvement (p = 0.68). Multivariate logistic analysis demonstrated that only pre-operative TNT (OR:2.35; 95% CI 1.06–5.25; p = 0.03) was predictive of pCR, while extramural vascular invasion (EMVI) was a predictor for lower rates of pCR (OR: 0.28; 95% CI 0.09–0.9; p = 0.03). CONCLUSION: Rectal cancer patients undergoing TNT prior to surgery have a higher chance of developing a complete pathologic response. Evaluation of this therapy should be continued and extended to larger numbers of patients to see if the differences we observed are real. |
format | Online Article Text |
id | pubmed-9555694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-95556942022-10-13 Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer Horesh, Nir Freund, Michael R. Garoufalia, Zoe Gefen, Rachel Nagarajan, Arun Suarez, Eva Emile, Sameh Hany Wexner, Steven D. J Gastrointest Surg Original Article INTRODUCTION: Total neoadjuvant therapy (TNT) is a new therapeutic strategy in patients with rectal cancer. We examined the role of TNT, in addition to other pre-operative factors, as a predictor for pathologic complete response (pCR). METHODS: A retrospective analysis of all rectal cancer patients who underwent surgery between 2016 and 2021 was conducted. Patients were classified into two groups—pCR group and residual tumor group. Patient data were reviewed and entered into univariate and multivariate analyses to determine predictors of pCR. RESULTS: A total of 172 patients were treated with neoadjuvant therapy and underwent surgery during the study period. Sixty patients (34.9%) were treated with TNT while 112 (65.1%) were treated with traditional neoadjuvant chemoradiation. The overall pCR rate was 25.6% (44 patients), with 31.6% (19 patients) in patients who received TNT compared to 22.3% (25 patients) in patients who received neoadjuvant chemoradiation (NCRT). Univariate analysis of clinical and radiological factors correlated with pCR demonstrated no significant differences between the two groups in cT stage (p = 0.46), cN stage (p = 0.52), positive circumferential resection margin (CRM) (p = 0.72), tumor location (p = 0.35), symptomatic presentation (p = 0.09), and anal sphincter involvement (p = 0.68). Multivariate logistic analysis demonstrated that only pre-operative TNT (OR:2.35; 95% CI 1.06–5.25; p = 0.03) was predictive of pCR, while extramural vascular invasion (EMVI) was a predictor for lower rates of pCR (OR: 0.28; 95% CI 0.09–0.9; p = 0.03). CONCLUSION: Rectal cancer patients undergoing TNT prior to surgery have a higher chance of developing a complete pathologic response. Evaluation of this therapy should be continued and extended to larger numbers of patients to see if the differences we observed are real. Springer US 2022-10-12 2022 /pmc/articles/PMC9555694/ /pubmed/36224480 http://dx.doi.org/10.1007/s11605-022-05463-1 Text en © The Society for Surgery of the Alimentary Tract 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Horesh, Nir Freund, Michael R. Garoufalia, Zoe Gefen, Rachel Nagarajan, Arun Suarez, Eva Emile, Sameh Hany Wexner, Steven D. Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer |
title | Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer |
title_full | Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer |
title_fullStr | Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer |
title_full_unstemmed | Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer |
title_short | Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer |
title_sort | total neoadjuvant therapy is a predictor for complete pathological response in patients undergoing surgery for rectal cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555694/ https://www.ncbi.nlm.nih.gov/pubmed/36224480 http://dx.doi.org/10.1007/s11605-022-05463-1 |
work_keys_str_mv | AT horeshnir totalneoadjuvanttherapyisapredictorforcompletepathologicalresponseinpatientsundergoingsurgeryforrectalcancer AT freundmichaelr totalneoadjuvanttherapyisapredictorforcompletepathologicalresponseinpatientsundergoingsurgeryforrectalcancer AT garoufaliazoe totalneoadjuvanttherapyisapredictorforcompletepathologicalresponseinpatientsundergoingsurgeryforrectalcancer AT gefenrachel totalneoadjuvanttherapyisapredictorforcompletepathologicalresponseinpatientsundergoingsurgeryforrectalcancer AT nagarajanarun totalneoadjuvanttherapyisapredictorforcompletepathologicalresponseinpatientsundergoingsurgeryforrectalcancer AT suarezeva totalneoadjuvanttherapyisapredictorforcompletepathologicalresponseinpatientsundergoingsurgeryforrectalcancer AT emilesamehhany totalneoadjuvanttherapyisapredictorforcompletepathologicalresponseinpatientsundergoingsurgeryforrectalcancer AT wexnerstevend totalneoadjuvanttherapyisapredictorforcompletepathologicalresponseinpatientsundergoingsurgeryforrectalcancer |